Sugi Predict

Sugi Predict / Compounds / SCHEMBL9960174

SCHEMBL9960174

SCHEMBL9960174

CN(C(=O)Cl)c1ccc(F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ PKM P14618 1/20 0.43
▸ CA1 P00915 2/20 0.41
▸ CA2 P00918 2/20 0.41
▸ GPBAR1 Q8TDU6 2/20 0.41
▸ APP P05067 3/20 0.41
▸ POLQ O75417 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ CES2 O00748 1/20 0.39
▸ CES1 P23141 1/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ SNCA P37840 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31009210 0.86 POLQ (0.45) GAAMAPTPKMCA1CA2
SCHEMBL7051493 0.82 S100A4 (0.42) CA1CA2APPCES2CES1
SCHEMBL12550514 0.82 GAA (0.49) GAAMAPTPKMCA1CA2
SCHEMBL8986913 0.80 ALDH1A1 (0.48) MAPTCA1CA2GPBAR1CYP1A2
SCHEMBL11616779 0.80 ALDH1A1 (0.50) GAAMAPTGPBAR1CYP1A2CYP2C19
SCHEMBL2095324 0.80 GAA (0.44) GAAMAPTPKMGPBAR1APP
SCHEMBL2095320 0.80 GAA (0.44) GAAMAPTPKMGPBAR1APP
SCHEMBL6393684 0.80 SMN1; SMN2 (0.56) GAAMAPTPKMAPPPOLQ
SCHEMBL21592408 0.78 GAA (0.43) GAAMAPTPKMGPBAR1APP
SCHEMBL5318411 0.78 MAPT (0.43) GAAMAPTPKMGPBAR1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4608816-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF Monte Rosa Therapeutics AG (CH) 2025-09-03 — — EP disclosed
EP-4598901-A1 PYRROLIDINE AND IMIDAZOLIDINE BASED DNA POLYMERASE THETA INHIBITORS AND USE THEREOF Thomas Jefferson University (US) 2025-08-13 — — EP disclosed
CN-119585241-A AT2R antagonists and uses thereof 伊莱利利公司 2025-03-07 — — CN disclosed
US-20250074875-A1 AT2R ANTAGONISTS AND USES THEREOF ELI LILLY AND COMPANY 2025-03-06 — — US disclosed
US-12122750-B2 AT2R antagonists and uses thereof ELI LILLY AND COMPANY (US) 2024-10-22 — — US disclosed
WO-2024147972-A2 DNA POLYMERASE THETA INHIBITORS CONTAINING NON-SATURATED 5-MEMBERED HETEROCYCLIC RINGS AND USE THEREOF THOMAS JEFFERSON UNIVERSITY (US) 2024-07-11 — — WO disclosed
WO-2024147972-A2 DNA POLYMERASE THETA INHIBITORS CONTAINING NON-SATURATED 5-MEMBERED HETEROCYCLIC RINGS AND USE THEREOF THOMAS JEFFERSON UNIVERSITY (US) 2024-07-11 — — WO disclosed
WO-2024092039-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2024-05-02 — — WO disclosed
WO-2024076964-A1 PYRROLIDINE AND IMIDAZOLIDINE BASED DNA POLYMERASE THETA INHIBITORS AND USE THEREOF THOMAS JEFFERSON UNIVERSITY (US) 2024-04-11 — — WO disclosed
WO-2023224853-A1 AT2R ANTAGONISTS AND USES THEREOF ELI LILLY AND COMPANY (US) 2023-11-23 — — WO disclosed
CN-103402977-B Ingenol-3-acylate III and ingenol-3-carbamate LEO PHARMA A/S (IE) 2016-01-20 — — CN disclosed
US-20150291551-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LIMITED (IE) 2015-10-15 — — US disclosed
US-9102687-B2 Ingenol-3-acylates III and ingenol-3-carbamates LEO LABORATORIES LIMITED (IE) 2015-08-11 — — US disclosed
CN-104529827-A Ingenol-3-acylates III and ingenol-3-carbamates LEO PHARMA AS 2015-04-22 — — CN disclosed
US-20140303150-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LIMITED (IE) 2014-10-09 — — US disclosed
EP-2655323-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LIMITED (IE) 2013-10-30 — — EP disclosed
WO-2012083953-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO PHARMA A/S (DK) 2012-06-28 — — WO disclosed
US-4136180-A HYPOLIPIDEMIC SUBSTITUTED STYRENESULFONYLUREAS PFIZER INC. (US) 1979-01-23 — — US disclosed
US-4062960-A Hypolipidemic alkenesulfonamides PFIZER INC. (US) 1977-12-13 — — US disclosed
US-3983107-A ARTERIOSCLEROSIS PFIZER INC. (US) 1976-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150291551-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES RXRB, RXRA, RXRG GAA 3648/4885MAPT 4738/4885PKM 3777/4885
US-20140303150-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES RXRB, RXRA, RXRG GAA 3648/4885MAPT 4738/4885PKM 3777/4885
US-20250074875-A1 AT2R ANTAGONISTS AND USES THEREOF AGTR2, AGTR1, AVPR2 GAA 4330/4885MAPT 3277/4885PKM 1721/4885
US-12122750-B2 AT2R antagonists and uses thereof AGTR2, AGTR1, AVPR2 GAA 4319/4885MAPT 3281/4885PKM 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.